title: [In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].
abstract: Minimal inhibitory concentrations (MICs) of sparfloxacin (SFX) were determined by agar dilution for 3,164 bacterial strains isolated in 10 university hospitals; in addition, antibiograms by agar diffusion were performed with 5 micrograms disks. Activity of SFX against nalidixic acid (NAL) susceptible (S) Enterobacteriaceae was close to that of other fluoroquinolones (FQ) (MIC 50 and 90: 0.06-0.5 microgram/ml); like for other FQ, this activity was reduced against NAL intermediate and resistant (R) Enterobacteriaceae (2-16). MICs of SFX against P. aeruginosa were between 0.12 and 16 (1-32). SFX had also a good activity against NAL-S A. baumannii (CMI < or = 0.25) but this activity is reduced against NAL-R Acinetobacter (16). SFX was highly active against Haemophilus (0.016-0.06) gonococci (0.008), meningococci (0.008) and B. catarrhalis (0.008-0.03). SFX showed activity superior to the currently available FQ against methicillin susceptible staphylococci (0.06); the resistant strains [8] are usually methicillin resistant. SFX is more effective against enterococci (0.5), streptococci (0.25-0.5) and particularly pneumococci (0.25-0.5) including penicillin-resistant strains. The coefficient correlation of the regression curve is 0.876; for MIC breakpoints of 1 and 2 micrograms/ml, zone diameter breakpoints should be 20 and 16 mm.
authors.affiliation: Service de Bactériologie, CHU Henri-Mondor, Créteil, France.
authors.forename: C J
authors.initials: CJ
authors.lastname: Soussy
authors.forename: M
authors.initials: M
authors.lastname: Cluzel
authors.forename: E
authors.initials: E
authors.lastname: Derlot
authors.forename: L
authors.initials: L
authors.lastname: Exmelin
authors.forename: M D
authors.initials: MD
authors.lastname: Kitzis
authors.forename: H
authors.initials: H
authors.lastname: Dabernat
authors.forename: P
authors.initials: P
authors.lastname: Le Noc
authors.forename: C
authors.initials: C
authors.lastname: Muller-Serieys
authors.forename: M E
authors.initials: ME
authors.lastname: Reverdy
authors.forename: J M
authors.initials: JM
authors.lastname: Scheftel
authors.forename: A
authors.initials: A
authors.lastname: Thabaut
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects / Q000302:isolation & purification; D003428:Cross Infection / Q000382:microbiology*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D004926:Escherichia coli / Q000187:drug effects / Q000302:isolation & purification; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D066298:In Vitro Techniques; D015363:Quinolones / Q000494:pharmacology*; D012044:Regression Analysis
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C061363:sparfloxacin
vernacular_title: Activité anti-bactérienne in vitro d'une nouvelle fluoroquinolone, la sparfloxacine sur les bactéries hospitalières et courbe de concordance.